Moreover, ABR-238901 treatment significantly decreased the severity of cardiac hypertrophy (reduced LV wall thickness, LV volume, HW/TL ratio, and cardiac myocyte areas) and fibrosis (fibrotic areas, α-SMA-positive areas and COL3A1-positive areas), as well as decreased the mRNA expression of ANP, BNP, α-SMA, and COL1A1 in the heart, compared with the vehicle control post-TAC (Figure 8E-J). Here, ACTA1 is linked to cardiac hypertrophy.